# Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali

> **NCT02535767** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 28 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Primaquine

## Key facts

- **NCT ID:** NCT02535767
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535767, "Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02535767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*